금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Swiss Franc eyes first weekly gain in five weeks as weak NFP delays Fed hikes
USD/CHF heads for its first weekly loss in five weeks as weaker-than-expected US Nonfarm Payrolls (N...
Pound Sterling Price News and Forecast: GBP/USD holds weekly gains as Fed hike doubts deepen
The British Pound steadied against the US Dollar on Friday, but it is poised to end the week with ga...
WTI Crude Oil advances on softer US jobs data and lingering Middle East tensions
West Texas Intermediate (WTI) trades around $68.65 at the time of writing on Friday, up 0.30% on the...
AppLovin Stock Is Having a Bad Year. Why It’s Today’s Top Performer in the S&P 500.
AppLovin was the top performer in the on Wednesday after analysts at Morgan Stanley counseled investors to buy the stock. Shares of the mobile advertising platform jumped 11% to $569.96, putting ...
MGM Resorts Jumps Above Buy Point, Leads S&P 500 As Analysts See Las Vegas Rebound
MGM Resorts International gapped above a buy point Wednesday after two analysts upgraded the stock, citing improving Las Vegas trends. MGM stock is the best-performer in the S&P 500 today. JPMorgan ...
TrueBlue rejects offer from HireQuest for On-Demand business
Apple ups trade-in values for array of devices ahead of WWDC
Movado sees Q2 sales growth moderating while raising quarterly dividend to $0.40
Cullen/Frost Soars Nearly 13% in 6 Months: Is It Worth Buying Now?
Can CFR extend its 12.8% six-month rally as Texas expansion, revenue growth and solid capital returns continue to drive its long-term outlook? Let us find out.
3 Reasons TCBI is Risky and 1 Stock to Buy Instead
Texas Capital Bank trades at $99.82 per share and has stayed right on track with the overall market, gaining 10.7% over the last six months. At the same time, the S&P 500 has returned 9.1%.
Seanergy Maritime Q1 2026 Earnings Preview
Momentus’s stock nearly triples in 2 days as the space company raises more cash from investors
Momentus investors continue to cheer as the space firm secures more cash through a private placement of stock.
AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant
Futu Holdings Q1 2026 Earnings Preview